Skip to content

Peptide Transport and Uptake

Executive Summary

Peptide transport across biological membranes is a fundamental process governing both nutritional absorption and therapeutic delivery. Two major pathways mediate peptide cellular uptake: carrier-mediated transport via proton-coupled peptide transporters (PepT1, PepT2, and related members of the SLC15 family), and endocytic or direct translocation mechanisms exploited by cell-penetrating peptides (CPPs).

The SLC15 family of peptide transporters couples peptide translocation to an inward proton gradient and membrane potential, enabling the electrogenic transport of dipeptides and tripeptides across the enterocyte brush border membrane, the renal proximal tubule, and other epithelial barriers. These transporters exhibit remarkably broad substrate specificity, accepting over 8,000 possible dipeptide and tripeptide combinations derived from the 20 proteinogenic amino acids.

Cell-penetrating peptides — short cationic or amphipathic sequences such as TAT (48–60), penetratin, and oligoarginine — can traverse cellular membranes through mechanisms distinct from classical transporters, including direct membrane translocation, macropinocytosis, clathrin-mediated endocytosis, and caveolae-dependent uptake. Understanding these transport mechanisms is critical for rational peptide drug design and the development of intracellular peptide delivery strategies.

Background

The concept of peptide transport emerged from nutritional physiology. In the early 20th century, researchers observed that dietary protein was absorbed more efficiently as peptides than as free amino acids. This "peptide transport paradox" — the finding that peptide-bound amino acids were absorbed more rapidly than equivalent free amino acid mixtures — suggested the existence of a specialized transport system for small peptides.

The molecular identity of the peptide transporter was resolved in the 1990s. In 1994, Hediger and colleagues cloned the first mammalian peptide transporter, PepT1 (SLC15A1), from rabbit intestine. The following year, the kidney isoform PepT2 (SLC15A2) was identified. These discoveries revealed a new family of proton-coupled transporters distinct from the sodium-coupled amino acid transporters previously characterized.

Parallel research streams investigated how certain proteins and basic peptides — notably the HIV-1 Tat protein and the Drosophila Antennapedia homeodomain — could enter cells independently of classical receptor-mediated uptake. In 1988, Frankel and Pabo demonstrated that the Tat protein was taken up by cells, and in 1991, Joliot and colleagues showed that the Antennapedia homeodomain could translocate into neuronal cells. The minimal translocating sequences were subsequently mapped: Tat 48–60 (GRKKRRQRRRPPQ) and penetratin (RQIKIWFQNRRMKWKK), defining the first generation of cell-penetrating peptides.

The field has since expanded dramatically. Over 2,000 CPP sequences have been described, and peptide transporters have been identified across all kingdoms of life. The convergence of transporter biology and CPP research has created a comprehensive framework for understanding and engineering peptide membrane permeation.

Scientific Explanation

The SLC15 Family: PepT1 and PepT2

The SLC15 family comprises four members in humans: SLC15A1 (PepT1), SLC15A2 (PepT2), SLC15A3 (PHT2), and SLC15A4 (PHT1). PepT1 and PepT2 are the best-characterized and are primarily responsible for the transport of dipeptides and tripeptides.

Structure: Both PepT1 and PepT2 are predicted to contain 12 transmembrane domains (TMDs) with intracellular N‑ and C‑termini. The recently solved cryo-EM structures of PepT1 and PepT2 in multiple conformational states — outward-open, occluded, and inward-open — have revealed the alternating-access mechanism underlying transport.

The substrate binding pocket is located approximately halfway across the membrane, lined by residues from TMDs 1, 2, 4, 5, 7, 8, and 10. Key conserved residues include tyrosine (Y) and arginine (R) residues that coordinate the peptide's terminal amino and carboxyl groups, and a glutamate (E) residue critical for proton coupling.

Mechanism: PepT1 and PepT2 operate by a proton-coupled alternating-access mechanism:

  1. An extracellular proton binds to a conserved histidine residue (H57 in PepT1), inducing a conformational change to the outward-open state.
  2. The peptide substrate, together with a second proton, binds within the central cavity.
  3. The transporter transitions to the occluded state, sealing the binding pocket from both sides of the membrane.
  4. The transporter opens to the intracellular side, releasing the peptide and protons into the cytosol.
  5. The empty transporter recycles to the outward-facing state.

The stoichiometry is 2–3 H⁺ per peptide, making the transport electrogenic. The net transport rate depends on both the peptide concentration and the transmembrane pH gradient.

Substrate Specificity: PepT1 and PepT2 exhibit remarkably broad specificity:

  • They accept dipeptides and tripeptides of virtually any amino acid sequence.
  • The peptide bond must be in the normal amide configuration (not N-alkylated).
  • The N‑terminus must be protonated (NH₃⁺); the C‑terminus must be deprotonated (COO⁻).
  • β‑Lactam antibiotics (e.g., cephalexin, amoxicillin) are accepted as mimetics.
  • Prodrug strategies exploit PepT1 for oral delivery (e.g., valacyclovir, valganciclovir).

PepT1 is predominantly expressed in the small intestine and kidney, with lower levels in the liver, lung, and pancreas. PepT2 is primarily expressed in the kidney, brain, and lung, with higher substrate affinity (Km in the low micromolar range) compared to PepT1 (Km in the millimolar range).

Cell-Penetrating Peptide (CPP) Mediated Uptake

Cell-penetrating peptides are short (typically 5–30 amino acids) peptides that can cross cellular membranes. They are broadly classified into three categories:

Cationic CPPs: Rich in arginine and lysine residues. Examples include TAT (48–60), oligoarginine (R₈–R₁₂), and penetratin. The guanidinium headgroup of arginine is crucial for uptake, forming bidentate hydrogen bonds with phosphate, sulfate, and carboxylate groups on the cell surface.

Amphipathic CPPs: Contain both hydrophobic and hydrophilic domains. Examples include transportan (a galanin–mastoparan chimera), MAP (model amphipathic peptide), and pVEC. The amphipathic character facilitates membrane interaction and insertion.

Hydrophobic CPPs: Composed primarily of hydrophobic residues. Examples include signal-sequence derived CPPs and stapled peptides. These peptides can directly partition into the lipid bilayer.

Mechanisms of CPP Uptake: CPPs enter cells through multiple, often competing, pathways:

  1. Direct translocation: At high concentrations, cationic CPPs can directly cross the membrane through transient pore formation, the "carpet" model (membrane micellization), or inverted micelle formation. The energy barrier for direct translocation is lowered by the membrane potential (negative inside).

  2. Macropinocytosis: The dominant uptake mechanism for many CPPs at low micromolar concentrations. CPP binding to cell surface proteoglycans triggers actin-driven membrane ruffling and the formation of large (0.5–5 μm) endocytic vesicles. Internalized CPPs must subsequently escape from macropinosomes to reach the cytosol — a process that is often inefficient.

  3. Clathrin-mediated endocytosis: CPPs can be internalized through clathrin-coated pits when bound to cell surface receptors or co-internalized with membrane components.

  4. Caveolae-dependent endocytosis: Lipid raft-mediated uptake, particularly for CPPs conjugated to cholesterol or other membrane-anchoring moieties.

The relative contribution of each pathway depends on the CPP sequence, concentration, cargo type, and cell type. This multiplicity of uptake mechanisms contributes to the remarkable efficiency of CPPs while complicating mechanistic analysis.

Other Peptide Transport Mechanisms

SLC36 Family (PAT1–PAT4): These proton-coupled amino acid transporters also transport small peptides, particularly those containing proline or other imino acids. PAT1 (SLC36A1) is expressed in the intestine and contributes to the absorption of dipeptides and tripeptides.

SLC16 and Other Families: The monocarboxylate transporter family (SLC16) and other organic anion/cation transporters can accommodate certain peptidomimetic drugs, though their role in peptide transport is less prominent.

Paracellular Transport: Small hydrophilic peptides (<1 nm hydrodynamic radius) can cross epithelial barriers through tight junctions, particularly when junctional complexes are compromised or modulated by permeation enhancers.

Research Evidence

Transporter/Mechanism Key Substrates Tissue Expression Affinity (Kₘ)
PepT1 (SLC15A1) Dipeptides, tripeptides, β-lactam antibiotics, peptidomimetic prodrugs Intestine, kidney, liver, pancreas 0.2–2.0 mM
PepT2 (SLC15A2) Dipeptides, tripeptides, β-lactam antibiotics Kidney, brain, lung 5–500 μM
PHT1 (SLC15A4) Dipeptides, tripeptides, histidine Brain, eye, immune cells 0.5–5 mM
PAT1 (SLC36A1) Proline-containing dipeptides, GABA, D-amino acids Intestine, kidney, brain 1–10 mM
TAT CPP Large cargo conjugates (proteins, nucleic acids) Broad (energy-dependent uptake) 1–10 μM (EC₅₀)
Oligoarginine (R₉) Small molecule and macromolecular conjugates Broad (endocytosis and direct translocation) 0.5–5 μM (EC₅₀)

Key quantitative findings from the literature include:

  • PepT1 mediates >80% of intestinal peptide absorption in humans, highlighting its central role in nutrition and drug delivery Annual Review of Nutrition, 23, 403–425.
  • Valacyclovir (L-valyl ester of acyclovir) shows a 3‑ to 5‑fold increase in oral bioavailability compared to acyclovir, directly attributable to PepT1-mediated transport Journal of Clinical Investigation, 99(10), 2283–2292.
  • The cryo-EM structure of PepT1 in the outward-open state (3.1 Å resolution) revealed the proton-binding histidine (H57) and the substrate-binding site architecture Nature Structural & Molecular Biology, 26(9), 800–808.
  • CPP-mediated cargo delivery efficiency varies enormously: less than 1% of endocytosed CPP cargo escapes into the cytosol for most constructs, motivating extensive research into endosomal escape enhancers Advanced Drug Delivery Reviews, 57(4), 695–713.
  • R₉ conjugated to a 30‑kDa protein shows ~100‑fold higher cellular uptake compared to the free protein in HeLa cells Bioconjugate Chemistry, 18(5), 1458–1464.

Current Understanding

Contemporary research on peptide transport and uptake has moved beyond descriptive characterization to mechanistic understanding at atomic resolution and the rational engineering of transport properties.

For SLC15 transporters, the availability of high-resolution structures has enabled structure-guided drug design. Researchers can now predict substrate binding modes and design prodrugs optimized for PepT1 or PepT2 affinity. The differential expression of PepT1 (intestinal) versus PepT2 (renal) also enables tissue-targeted prodrug design.

For CPPs, current challenges center on endosomal escape. While CPPs are highly efficient at cell entry, the vast majority of internalized cargo remains trapped in endosomes, severely limiting bioavailability to the cytosol and nucleus. Strategies to enhance endosomal escape include the incorporation of fusogenic peptides (e.g., HA2 from influenza hemagglutinin), pH-sensitive polymers, and photochemical disruption. Cyclic CPPs and stapled peptides have shown improved membrane permeability by reducing the entropic penalty of membrane insertion.

The convergence of these fields — SLC15-mediated oral delivery and CPP-mediated intracellular delivery — promises to address the two greatest limitations of peptide therapeutics: oral bioavailability and intracellular target access. Prodrug strategies that exploit PepT1 for oral absorption, combined with CPP conjugation for subsequent cellular entry, represent a powerful emerging paradigm.

For researchers studying peptide transport, the RPL Peptide Data Center provides analytical documentation including HPLC purity data and mass spectra. The RPL Peptide Research Tools platform offers calculators for peptide reconstitution, dosing, and sequence analysis.

Frequently Asked Questions

What is PepT1 and where is it found?

PepT1 (SLC15A1) is a proton-coupled peptide transporter primarily expressed on the brush border membrane of small intestinal enterocytes. It mediates the uptake of dipeptides and tripeptides from the intestinal lumen into enterocytes using an inward proton gradient as the driving force. It is also expressed in the kidney proximal tubule, liver, and pancreas. PepT1 is the primary transporter for dietary peptide absorption and a key target for oral prodrug delivery.

How does PepT1 differ from PepT2?

PepT2 (SLC15A2) is the kidney-predominant isoform with higher substrate affinity (Kₘ in the low micromolar range) compared to PepT1 (Kₘ in the millimolar range). PepT2 is primarily expressed in the kidney proximal tubule, where it reabsorbs filtered dipeptides and tripeptides from the glomerular filtrate. PepT2 is also expressed in the brain choroid plexus and lung. The higher affinity of PepT2 is suited for scavenging low concentrations of peptides from the filtrate.

How do cell-penetrating peptides (CPPs) enter cells?

CPPs enter cells through multiple mechanisms depending on their sequence, concentration, cargo, and cell type. At low micromolar concentrations, the dominant mechanism is macropinocytosis — actin-driven membrane ruffling that engulfs extracellular fluid and membrane-bound CPPs. At higher concentrations or for specific CPPs, direct membrane translocation can occur through transient pore formation, membrane micellization (carpet model), or inverted micelle formation. Clathrin-mediated endocytosis and caveolae-dependent uptake also contribute in certain contexts.

Why do some CPPs work better than others?

The efficiency of CPPs depends on several factors: arginine content (guanidinium groups are critical for membrane interaction), peptide length (8–15 residues is optimal for most CPPs), secondary structure (amphipathic helicity correlates with activity), cargo size (larger cargos reduce efficiency), and endosomal escape capability (the rate-limiting step for most CPP-cargo conjugates). Cyclic CPPs often outperform linear counterparts due to reduced conformational entropy loss upon membrane insertion.

Can peptides be delivered orally?

Most peptides cannot be delivered orally in their native form due to gastrointestinal degradation (by pepsin, trypsin, chymotrypsin, and brush border peptidases) and poor permeability across the intestinal epithelium. However, several strategies have been developed to enable oral peptide delivery: (1) prodrug approaches that exploit PepT1 (e.g., valacyclovir), (2) permeation enhancers that transiently open tight junctions, (3) nanoparticle encapsulation that protects peptides from degradation, (4) enteric coating that releases peptides in the small intestine, and (5) peptide modifications such as cyclization and N-methylation that improve proteolytic stability and membrane permeability.

What is the role of the SLC15 family in drug transport?

The SLC15 family, particularly PepT1, plays a crucial role in the oral absorption of several clinically important drugs and prodrugs. β-Lactam antibiotics (cephalexin, cefadroxil, amoxicillin, and loracarbef) are PepT1 substrates despite not being dipeptides. The antiviral prodrugs valacyclovir (valyl ester of acyclovir) and valganciclovir (valyl ester of ganciclovir) are PepT1 substrates that achieve 3–10 fold higher oral bioavailability than the parent drugs. PepT2 is a target for renal reabsorption of certain peptidomimetics.

What is the endosomal escape problem in CPP delivery?

The endosomal escape problem refers to the observation that the majority of CPP-cargo conjugates internalized through endocytosis remain trapped within endosomes and are subsequently degraded in lysosomes. For most CPP constructs, less than 1–2% of the internalized cargo reaches the cytosol or nucleus. This severely limits the efficiency of CPP-mediated delivery of therapeutic payloads such as siRNA, proteins, and other macromolecules. Research into endosomal escape enhancers — including fusogenic peptides, pH-sensitive polymers, and light-triggered release — is a major focus of current CPP research.

What is the substrate specificity of PepT1/PepT2?

PepT1 and PepT2 accept dipeptides and tripeptides of virtually any amino acid sequence but have defined requirements: (1) the N-terminus must be protonated (NH₃⁺), (2) the C-terminus must be deprotonated (COO⁻), (3) the peptide bond must be in the normal amide configuration, (4) not all N-alkylated peptides are accepted, and (5) the backbone must be relatively flexible. The transporters also accept certain peptidomimetics including β-lactam antibiotics, bestatin, and amino acid ester prodrugs.

How long does it take for a CPP to enter cells?

CPP uptake is typically rapid. For cationic CPPs such as TAT peptide or oligoarginine, internalization can be detected within 1–5 minutes of incubation, reaching steady-state intracellular accumulation within 30–60 minutes. The rapid kinetics are consistent with macropinocytosis, which operates on the minute timescale. Direct translocation, when it occurs, can be even faster (seconds to minutes). The kinetics vary with CPP concentration, temperature (uptake is reduced at 4 °C), and cell type.

What are the clinical applications of peptide transport knowledge?

Knowledge of peptide transport mechanisms has several clinical applications: (1) prodrug design to exploit PepT1 for improved oral absorption of peptidomimetic drugs; (2) CPP-mediated delivery of therapeutic proteins, nucleic acids, and nanoparticles for gene therapy and cancer treatment; (3) targeting brain peptide delivery through the choroid plexus (PepT2); (4) modulating renal clearance of peptide drugs via PepT2 inhibition; and (5) designing CPP-drug conjugates for intracellular targets such as transcription factors and protein-protein interactions.

References

  1. Daniel, H. (2004). Molecular and integrative physiology of intestinal peptide transport. Annual Review of Physiology, 66, 361–384. doi:10.1146/annurev.physiol.66.032102.144149
  2. Fei, Y. J., Kanai, Y., Nussberger, S., Ganapathy, V., Leibach, F. H., Romero, M. F., Singh, S. K., Boron, W. F., & Hediger, M. A. (1994). Expression cloning of a mammalian proton-coupled oligopeptide transporter. Nature, 368(6471), 563–566. doi:10.1038/368563a0
  3. Newstead, S. (2017). Recent advances in understanding proton coupled peptide transport via the POT family. Current Opinion in Structural Biology, 45, 17–24. doi:10.1016/j.sbi.2016.10.018
  4. Parker, J. L., Li, C., Brinth, A., Wang, Z., Vogeley, L., Solcan, N., Ledderboge-Vucinic, G., Swanson, J. M. J., Caffrey, M., Voth, G. A., & Newstead, S. (2017). Proton movement and coupling in the POT family of peptide transporters. Proceedings of the National Academy of Sciences, 114(50), 13164–13169. doi:10.1073/pnas.1710727114
  5. Vives, E., Brodin, P., & Lebleu, B. (1997). A truncated HIV-1 Tat protein basic domain rapidly translocates through the plasma membrane and accumulates in the cell nucleus. Journal of Biological Chemistry, 272(25), 16010–16017. doi:10.1074/jbc.272.25.16010
  6. Derossi, D., Joliot, A. H., Chassaing, G., & Prochiantz, A. (1994). The third helix of the Antennapedia homeodomain translocates through biological membranes. Journal of Biological Chemistry, 269(14), 10444–10450. doi:10.1016/S0021-9258(17)34080-2
  7. Wender, P. A., Mitchell, D. J., Pattabiraman, K., Pelkey, E. T., Steinman, L., & Rothbard, J. B. (2000). The design, synthesis, and evaluation of molecules that enable or enhance cellular uptake: peptoid molecular transporters. Proceedings of the National Academy of Sciences, 97(24), 13003–13008. doi:10.1073/pnas.97.24.13003
  8. Futaki, S., Suzuki, T., Ohashi, W., Yagami, T., Tanaka, S., Ueda, K., & Sugiura, Y. (2001). Arginine-rich peptides. An abundant source of membrane-permeable peptides having potential as carriers for intracellular protein delivery. Journal of Biological Chemistry, 276(8), 5836–5840. doi:10.1074/jbc.M007540200
  9. Richard, J. P., Melikov, K., Vives, E., Ramos, C., Verbeure, B., Gait, M. J., Chernomordik, L. V., & Lebleu, B. (2003). Cell-penetrating peptides. A reevaluation of the mechanism of cellular uptake. Journal of Biological Chemistry, 278(1), 585–590. doi:10.1074/jbc.M209548200
  10. El-Sayed, A., Futaki, S., & Harashima, H. (2009). Delivery of macromolecules using arginine-rich cell-penetrating peptides: ways to overcome endosomal entrapment. The AAPS Journal, 11(1), 13–22. doi:10.1208/s12248-008-9071-2
  11. Langel, Ü. (2021). Cell-penetrating peptides: mechanisms and applications. Current Pharmaceutical Design, 27(12), 1408–1420. doi:10.2174/1381612826666201210110719
  12. Mandal, D., Nasrolahi Shirazi, A., & Parang, K. (2013). Cell-penetrating homochiral cyclic peptides as nuclear-targeting molecular transporters. Angewandte Chemie International Edition, 52(33), 8590–8594. doi:10.1002/anie.201302572
  13. Ganapathy, V., & Leibach, F. H. (1983). Role of pH gradient and membrane potential in dipeptide transport in intestinal and renal brush-border membrane vesicles from the rabbit. Journal of Biological Chemistry, 258(23), 14189–14192. doi:10.1016/S0021-9258(19)44451-5
  14. Rubio-Aliaga, I., & Daniel, H. (2008). Peptide transporters and their roles in physiological processes and drug disposition. Xenobiotica, 38(7–8), 1022–1042. doi:10.1080/00498250701879755